Century Therapeutics (IPSC) Change in Accured Expenses (2020 - 2026)

Century Therapeutics (IPSC) has reported Change in Accured Expenses for 7 consecutive years, with -$4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 39.55% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$1.7 million (down 6.41% YoY), while the FY2025 annual figure was -$4.3 million, down 369.35% from the prior year.
• Change in Accured Expenses slipped to -$4.0 million in Q1 2026 per IPSC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.9 million in Q3 2023 and bottomed at -$6.5 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$202470.6 across 5 years, with a median of $707000.0 in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 310.87% — and 2025, when it surged 397.06%.
• Century Therapeutics' Change in Accured Expenses stood at $1.1 million in 2022, then sank by 310.87% to -$2.4 million in 2023, then soared by 221.74% to $2.9 million in 2024, then plunged by 62.87% to $1.1 million in 2025, then tumbled by 466.64% to -$4.0 million in 2026.
• Business Quant data shows IPSC's Change in Accured Expenses at -$4.0 million in Q1 2026, $1.1 million in Q4 2025, and $443000.0 in Q3 2025.